PE20091883A1 - Compuestos que comprenden un grupo ciclobutoxi - Google Patents
Compuestos que comprenden un grupo ciclobutoxiInfo
- Publication number
- PE20091883A1 PE20091883A1 PE2009000073A PE2009000073A PE20091883A1 PE 20091883 A1 PE20091883 A1 PE 20091883A1 PE 2009000073 A PE2009000073 A PE 2009000073A PE 2009000073 A PE2009000073 A PE 2009000073A PE 20091883 A1 PE20091883 A1 PE 20091883A1
- Authority
- PE
- Peru
- Prior art keywords
- oxy
- trans
- phenyl
- alkyl
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 3
- -1 AMINO Chemical group 0.000 abstract 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- FHIMYVFGWKCROK-UHFFFAOYSA-N [1,3]thiazolo[5,4-c]pyridine Chemical compound C1=NC=C2SC=NC2=C1 FHIMYVFGWKCROK-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 abstract 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES AMINO CILICO O ALIFATICO SUSTITUIDO O NO; A1 ES CH, C-HALOGENO, N; B ES HETEROARIL, HETEROCICLOALQUIL DE 5-8 MIEMBROS, CICLOALQUIL C5-C8; X ES O, S, NH, N-(ALQUIL C1-C4; Y ES O, S, NH; R1 ES SULFONIL, AMINO, ALQUILO C1-C6, ARIL, CICLOALQUIL C3-C8, ENTRE OTROS; n ES 0-3; R2 ES H, SULFONIL, AMINO, ARIL ACIL, FOSFONATO, ENTRE OTROS; m ES 0-1; R3 ES H, ALQUILO C1-C6, HALOGENO, ALCOXI C1-C6. SON COMPUESTOS PREFERIDOS: ACIDO 2-{4-[(TRANS-3-PIPERIDIN-1-ILCILOBUTIL)OXI]FENIL}-5,6-DIHIDRO-4H-CICLOPENTA[d][1,3]TIAZOLO[5,4-c]PIRIDINA; 5-ACETIL-2-{4-[(TRANS-3-AZEPAN-1-ILCICLOBUTIL)OXI]FENIL}-4,5,6,7-TETRAHIDRO[1,3]TIAZOLO[5,4-c]PIRIDINA; 3-OXO-3-[2-{4-[(TRANS-3-PIPERIDIN-1-CICLOBUTIL)OXI]FENIL}-6,7-DIHIDRO[1,3]-TIAZOLO[4,5-c]PIRIDIN-5(4H)-IL]PROPANAMIDA; ENTRE OTROS. DICHOS COMPUESTOS ACTUAN COMO LIGANDOS DEL RECEPTOR H3 SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDAD DE ALZHEIMER, ESQUIZOFRENIA, DEMENCIA, DEPRESION, EPILEPSIA, OBESIDAD, ENTRE OTROS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2320708P | 2008-01-24 | 2008-01-24 | |
| EP08001308 | 2008-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091883A1 true PE20091883A1 (es) | 2010-01-07 |
Family
ID=39490075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000073A PE20091883A1 (es) | 2008-01-24 | 2009-01-22 | Compuestos que comprenden un grupo ciclobutoxi |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100292188A1 (es) |
| EP (1) | EP2238144A1 (es) |
| JP (1) | JP2011510044A (es) |
| KR (1) | KR20100121629A (es) |
| CN (1) | CN101925606A (es) |
| AR (1) | AR070234A1 (es) |
| AU (1) | AU2009207693A1 (es) |
| BR (1) | BRPI0906556A2 (es) |
| CA (1) | CA2710474A1 (es) |
| CO (1) | CO6321170A2 (es) |
| DO (1) | DOP2010000229A (es) |
| EA (1) | EA201001205A1 (es) |
| IL (1) | IL206404A0 (es) |
| MX (1) | MX2010007587A (es) |
| NZ (1) | NZ586399A (es) |
| PE (1) | PE20091883A1 (es) |
| UY (1) | UY31611A1 (es) |
| WO (1) | WO2009092764A1 (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ611323A (en) | 2006-06-23 | 2014-10-31 | Abbvie Bahamas Ltd | Cyclopropyl amine derivatives as histamin h3 receptor modulators |
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| US20120029190A1 (en) * | 2009-04-03 | 2012-02-02 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| UY33027A (es) * | 2009-11-13 | 2011-06-30 | Astrazeneca Ab | Pirazina sustituida con oxazolo[4,5-c]piridina |
| USRE48301E1 (en) | 2010-07-09 | 2020-11-10 | Abbvie B.V. | Fused heterocyclic derivatives as S1P modulators |
| TWI522361B (zh) * | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| SI2611444T1 (sl) * | 2010-09-02 | 2016-04-29 | Suven Life Sciences Limited Serene Chambers | Spojine heterociklila kot ligandi receptorja histamina H3 |
| US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| WO2013076590A1 (en) | 2011-11-23 | 2013-05-30 | Oxygen Healthcare Research Pvt. Ltd | Benzothiazine compounds as h3 receptor ligands |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| LT3176170T (lt) | 2012-06-13 | 2019-04-25 | Incyte Holdings Corporation | Pakeisti tricikliniai junginiai, kaip fgfr inhibitoriai |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| MX393494B (es) | 2013-04-19 | 2025-03-24 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| BR112016007467B1 (pt) | 2013-10-04 | 2022-09-20 | Infinity Pharmaceuticals, Inc | Compostos heterocíclicos e usos dos mesmos |
| DK3119397T3 (da) | 2014-03-19 | 2022-03-28 | Infinity Pharmaceuticals Inc | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser |
| CN104059028B (zh) * | 2014-06-06 | 2020-10-16 | 北京智博高科生物技术有限公司 | 与Aβ斑块具有亲和力的含手性侧链取代的氟代2-芳基苯并杂环化合物、其制备方法及应用 |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10017520B2 (en) | 2014-12-10 | 2018-07-10 | Massachusetts Institute Of Technology | Myc modulators and uses thereof |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MA51229A (fr) | 2015-02-20 | 2021-03-24 | Incyte Corp | Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| NZ740616A (en) | 2015-09-14 | 2023-05-26 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2017143059A1 (en) | 2016-02-16 | 2017-08-24 | Massachusetts Institute Of Technology | Max binders as myc modulators and uses thereof |
| WO2017161119A1 (en) | 2016-03-16 | 2017-09-21 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Small molecules against cereblon to enhance effector t cell function |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EA202092649A1 (ru) | 2018-05-04 | 2021-06-21 | Инсайт Корпорейшн | Соли ингибитора fgfr |
| TWI870349B (zh) | 2018-05-04 | 2025-01-21 | 美商英塞特公司 | Fgfr抑制劑之固體形式及其製備方法 |
| ES2992256T3 (es) * | 2018-05-08 | 2024-12-11 | Nippon Shinyaku Co Ltd | Compuestos de azabencimidazol y producto farmacéutico |
| US11730726B2 (en) | 2018-07-11 | 2023-08-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN115835908A (zh) | 2019-10-14 | 2023-03-21 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR20220123634A (ko) | 2019-10-31 | 2022-09-08 | 이스케이프 바이오, 인크. | S1p-수용체 조절제의 고체 형태 |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2023505257A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| IL298760A (en) | 2020-06-05 | 2023-02-01 | Kinnate Biopharma Inc | Inhibitors of fibroblast growth factor receptor kinases |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CN117362316A (zh) * | 2023-10-07 | 2024-01-09 | 康龙化成手性医药技术(宁波)有限公司 | 一种四氢吡咯并噻唑类化合物的合成方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006228690A1 (en) * | 2005-03-31 | 2006-10-05 | Ucb Pharma S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
| ES2371774T3 (es) * | 2005-06-03 | 2012-01-10 | Abbott Laboratories | Derivados de ciclobutilamina. |
| US7576110B2 (en) * | 2005-09-22 | 2009-08-18 | Abbott Laboratories | Benzothiazole cyclobutyl amine derivatives |
-
2009
- 2009-01-22 CN CN2009801029945A patent/CN101925606A/zh active Pending
- 2009-01-22 NZ NZ586399A patent/NZ586399A/en not_active IP Right Cessation
- 2009-01-22 EA EA201001205A patent/EA201001205A1/ru unknown
- 2009-01-22 JP JP2010543497A patent/JP2011510044A/ja not_active Withdrawn
- 2009-01-22 AU AU2009207693A patent/AU2009207693A1/en not_active Abandoned
- 2009-01-22 EP EP09703770A patent/EP2238144A1/en not_active Withdrawn
- 2009-01-22 KR KR1020107018823A patent/KR20100121629A/ko not_active Withdrawn
- 2009-01-22 MX MX2010007587A patent/MX2010007587A/es not_active Application Discontinuation
- 2009-01-22 BR BRPI0906556-3A patent/BRPI0906556A2/pt not_active IP Right Cessation
- 2009-01-22 WO PCT/EP2009/050719 patent/WO2009092764A1/en active Application Filing
- 2009-01-22 PE PE2009000073A patent/PE20091883A1/es not_active Application Discontinuation
- 2009-01-22 CA CA2710474A patent/CA2710474A1/en not_active Abandoned
- 2009-01-22 US US12/812,719 patent/US20100292188A1/en not_active Abandoned
- 2009-01-23 UY UY031611A patent/UY31611A1/es unknown
- 2009-01-23 AR ARP090100203A patent/AR070234A1/es unknown
-
2010
- 2010-06-16 IL IL206404A patent/IL206404A0/en unknown
- 2010-07-09 CO CO10083721A patent/CO6321170A2/es not_active Application Discontinuation
- 2010-07-23 DO DO2010000229A patent/DOP2010000229A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009092764A1 (en) | 2009-07-30 |
| BRPI0906556A2 (pt) | 2015-07-07 |
| IL206404A0 (en) | 2010-12-30 |
| DOP2010000229A (es) | 2010-08-31 |
| US20100292188A1 (en) | 2010-11-18 |
| AR070234A1 (es) | 2010-03-25 |
| KR20100121629A (ko) | 2010-11-18 |
| CA2710474A1 (en) | 2009-07-30 |
| JP2011510044A (ja) | 2011-03-31 |
| MX2010007587A (es) | 2010-08-04 |
| EP2238144A1 (en) | 2010-10-13 |
| CN101925606A (zh) | 2010-12-22 |
| NZ586399A (en) | 2011-12-22 |
| UY31611A1 (es) | 2009-08-31 |
| EA201001205A1 (ru) | 2011-04-29 |
| CO6321170A2 (es) | 2011-09-20 |
| AU2009207693A1 (en) | 2009-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091883A1 (es) | Compuestos que comprenden un grupo ciclobutoxi | |
| ECSP099461A (es) | Compuesto heteromonocíclico y uso del mismo | |
| PE20141010A1 (es) | Derivados de piridin-2(1h)-ona utiles como medicamentos para el tratamiento de transtornos mieloproliferativos, rechazo de transplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
| AR070520A1 (es) | Derivados de azuleno nitrogenados,composiciones farmaceuticas que los contienen,proceso de preparacion y usos de los mismos para tratar trastornos metabolicos y digestivos,entre otros. | |
| PE20161223A1 (es) | Compuestos condensados de [1,4]diazepina como inhibidores de la produccion de autotaxina (atx) y acido lisofosfatidico (lpa) | |
| ES2567451T3 (es) | Compuestos de oxadiazoantraceno para el tratamiento de diabetes | |
| AR074358A1 (es) | Derivados de pirazina como inhibidores de la fosfodiesterasa 10 | |
| AR082885A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| PE20091756A1 (es) | Derivados de pirazolopirimidinona como moduladores de la pde9a | |
| PE20141973A1 (es) | Compuestos de heterociclilo como inhibidores de mek | |
| AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
| AR064299A1 (es) | Derivados de sulfonil-fenil-2h- [1,2,4] oxadiazol-5-ona procesos para su preparacion y su uso como agentes farmaceuticos | |
| AR081627A1 (es) | Compuestos heterociclicos de nitrogeno insaturados utiles como inhibidores de pde10 | |
| AR076164A1 (es) | Inhibidores de anillos fusionados de hepatitis c | |
| AR046020A1 (es) | Mimeticos de glucocorticoides, metodos de preparacion, composiciones farmaceuticas y usos de los mismos | |
| PE20140623A1 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
| PE20120172A1 (es) | Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
| PE20090480A1 (es) | Derivados de lactama tetraciclicos | |
| PE20121438A1 (es) | Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a | |
| AR071531A1 (es) | Compuesto cristalino heteromonociclico | |
| PE20110196A1 (es) | 5-alquinil-pirimidinas | |
| PE20130401A1 (es) | Heteroaril-ciclohexil-tetraazabenzo[e]azulenos | |
| PE20080988A1 (es) | Compuestos triciclicos fusionados de sulfonamida como inhibidores de gama-secretasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |